Is LianBio (LIANY) a Buy, Sell, or Hold?
OTC : LIANY
LianBio
$0.08 USD
$0 (0.0%)
- Volume
- 10K
- Average Volume
- 11.68K
- Market Capitalization
- $8.73M
- P/E Ratio
- 1.78
- Dividend Yield
- 537.50%
- Price Target
- Year High
- $0.18
- Year Low
- $0.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $9.65
- Current Ratio
- $1466.01
Company Overview
OTC
Adam Leo Stone
Biotechnology
Healthcare
LIANY
163
US
USD
Liquidity Metrics
0.00
1466.01
1466.01
670.43
9.65
Sales & Valuation
-$
0.00
0.43
1.76
0.05
Profitability
$0.045
$4.91M
0.00%
0.00%
11.78%
23.93%
P/E Metrics
1.78
0.00
0.00
Analyst Price Target & Rating
0/5
3 Analysts
%
Financial Health Scores
2.53
5/9
$577.44M
$617.96M
$36.77M
$310.93M
Key Metrics (TTM)
-$655.94K
0.00
0.52
1466.01
11.78%
-6.19%
56.25%
56.71%
$0.44
0 days
Company Executives
| Name | Title |
|---|---|
| Adam Leo Stone | Interim Chief Executive Officer & Director |
| Levvy Lv | Senior Vice President & Global Head of Development |
| Ji Chen | Senior Vice President & General Counsel |
| Brianne Jahn | Chief Business Officer |
| Brianne Puglisi | Chief Business Officer |
| Ehong Gu | Interim Chief Financial Officer, Vice President & Head of Global Finance |
| Konstantin Poukalov | Founder & Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About LianBio (OTC:LIANY) Stock
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses. These include mavacamten, aimed at both obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction. TP-03 is being developed for Demodex blepharitis and meibomian gland dysfunction. For cancer, LianBio is advancing NBTXR3 for head and neck squamous cell carcinoma and other solid tumors, alongside Infigratinib for chola ... ngiocarcinoma (both first-line and second-line settings) and gastric cancers, and BBP-398 also for solid tumors. Furthermore, Omilancor and NX-13 are in development for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other programs include LYR-210 for chronic rhinosinusitis and Sisunatovir to combat respiratory syncytial virus. LianBio has established key collaborations, partnering with Tarsus Pharmaceuticals, Inc. on the development and market introduction of TP-03 specifically for Demodex blepharitis. Additionally, it maintains a strategic alliance with Nanobiotix S.A. for NBTXR3, a novel radioenhancer intended for direct intratumoral injection before conventional radiation therapy. Established in 2019, the company's corporate headquarters are located in Princeton, New Jersey.
Frequently Asked Questions
-
What is the current LianBio (LIANY) stock price?
-
LianBio(OTC:LIANY) stock price is $0.08 in the last trading session. During the trading session, LIANY stock reached the peak price of $0.177 while $0.048 was the lowest point it dropped to. The percentage change in LIANY stock occurred in the recent session was 0.0% while the dollar amount for the price change in LIANY stock was $0.
-
LIANY's industry and sector of operation?
-
The OTC listed LIANY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LIANY?
-
Adam Leo Stone | Interim Chief Executive Officer & Director
Levvy Lv | Senior Vice President & Global Head of Development
Ji Chen | Senior Vice President & General Counsel
Brianne Jahn | Chief Business Officer
Brianne Puglisi | Chief Business Officer -
How many employees does LIANY have?
-
Number of LIANY employees currently stands at 163. LIANY operates from 103 Carnegie Center Drive, Princeton, NJ 08540, US.
-
Link for LIANY official website?
-
Official Website of LIANY is: https://www.lianbio.com
-
How do I contact LIANY?
-
LIANY could be contacted at phone #609 486 2308 and can also be accessed through its website. LIANY operates from 103 Carnegie Center Drive, Princeton, NJ 08540, US.
-
How many shares of LIANY are traded daily?
-
The average number of LIANY shares traded daily for last 3 months was 11.68K.
-
What is the market cap of LIANY currently?
-
The market value of LIANY currently stands at $8.73M with its latest stock price at $0.08